[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630492":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":25,"armGroups":21,"interventions":26,"overallOfficials":21,"centralContacts":21,"locations":21,"responsibleParty":30,"collaborators":21,"id":32,"slug":21,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":21,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":44,"studyType":45,"phases":21,"briefSummary":46,"conditions":47,"keywords":21,"overallStatus":49,"whyStopped":21,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":21},{"fullName":5,"class":6},"Acibadem University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)","Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.","Baseline and 14-21 days for test-retest assessment",[14,18],{"measure":15,"description":16,"timeFrame":17},"Self-Efficacy for Managing Chronic Disease (6-Item Scale)","Assessment of perceived self-efficacy in managing chronic disease using the 6-Item Self-Efficacy for Managing Chronic Disease Scale. The scale evaluates individuals' confidence in managing symptoms such as pain, fatigue, emotional distress, and disease-related problems. It consists of 6 items scored on a 10-point Likert scale (1 = not at all confident, 10 = totally confident), with the total score calculated as the mean of all items. Higher scores indicate greater self-efficacy in disease management. The validated Turkish version will be used.","Baseline",{"measure":19,"description":20,"timeFrame":17},"Montreal Cognitive Assessment (MoCA-TR)","Cognitive function will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR). This screening tool evaluates multiple cognitive domains including visuospatial\u002Fexecutive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function. The validated Turkish version for Parkinson's disease will be used.",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","CROSS_SECTIONAL","The study population will consist of individuals diagnosed with Parkinson's disease who are attending the Movement Disorders Outpatient Clinic at the Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital. Eligible participants will be between 40 and 85 years of age, have sufficient cognitive function to communicate (MMSE ≥ 24), and provide informed consent. A total of 100 patients will be recruited for the study.",[27],{"type":6,"name":28,"description":29,"armGroupLabels":21,"otherNames":21},"Cognitive Self-Efficacy Questionnaire (Turkish Version)","Participants will complete the Turkish version of the Cognitive Self-Efficacy Questionnaire to assess cognitive self-efficacy. The questionnaire will be administered for the evaluation of its validity and reliability in individuals with Parkinson's disease.",{"type":31,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100630492",false,"NCT07488377","Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease","Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire in Individuals With Parkinson's Disease","Inclusion Criteria:\n\n* Clinically diagnosed with Parkinson's disease\n\nAged between 40 and 85 years\n\nMMSE score ≥ 24 (adequate cognitive level for communication)\n\nVoluntary participation with informed consent\n\nPatients attending the Movement Disorders Outpatient Clinic, Department of Neurology\n\nExclusion Criteria:\n\n* Presence of psychiatric disorders (major depression, psychotic disorders)\n\nDiagnosis of advanced dementia\n\nSevere visual or hearing impairment that may interfere with assessments\n\nInability to cooperate with the physiotherapist or complete the assessments","ALL","40 Years","85 Years",{"count":42,"type":43},100,"ESTIMATED","2 Months","OBSERVATIONAL","This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.",[48],"Parkinson Disease","NOT_YET_RECRUITING","2026-03-18",{"date":52,"type":53},"2026-03-23","ACTUAL",{"date":55,"type":43},"2026-04-01",{"date":57,"type":43},"2027-04-01",{"name":5,"class":6}]